Refractory Mycosis(难治性真菌病)研究综述
Refractory Mycosis 难治性真菌病 - Purpose Management of patients with refractory mycosis fungoides and Sézary syndrome (SS) is often challenging, as available therapies lack durable response and consistent activity across disease compartments. [1] PD-L1 structural variants in relapsed/refractory mycosis fungoides should prompt consideration of treatment with PD-1 inhibitors. [2] Mogamulizumab was compared with vorinostat in the phase 3 MAVORIC trial (NCT01728805) in 372 patients with relapsed/refractory mycosis fungoides (MF) or Sézary syndrome (SS) who had failed ≥1 prior systemic therapy. [3] This phase 1 study evaluated the safety and activity of TTI-621 in patients with percutaneously accessible relapsed or refractory mycosis fungoides, Sézary syndrome, or solid tumours. [4] We herein describe two Japanese patients with heavily‐pretreated relapsed/refractory mycosis fungoides that were successfully controlled by pralatrexate. [5] BACKGROUND Mogamulizumab is a humanized antibody against chemokine receptor type 4 recently FDA approved for relapsed/refractory mycosis fungoides (MF) and Sézary syndrome (SS). [6] vorinostat in relapsed/refractory mycosis fungoides (MF) and Sézary syndrome (SS). [7] Context Mogamulizumab is an anti-CCR4 antibody for patients with relapsed/refractory mycosis fungoides (MF) or Sezary syndrome (SS). [8] Food and Drug Administration for relapsed or refractory mycosis fungoides (MF) or SS following failure of at least one previous course of systemic therapy. [9]难治性蕈样肉芽肿和 Sézary 综合征 (SS) 患者的管理通常具有挑战性，因为现有疗法缺乏持久的反应和跨疾病隔室的一致活动。 [1] 复发/难治性蕈样肉芽肿中的 PD-L1 结构变异应促使考虑使用 PD-1 抑制剂进行治疗。 [2] 在 372 例复发/难治性蕈样肉芽肿 (MF) 或 Sézary 综合征 (SS) 患者中进行了 3 期 MAVORIC 试验 (NCT01728805)，将莫加木单抗与伏立诺他进行了比较，这些患者之前的全身治疗失败了 ≥1 次。 [3] 这项 1 期研究评估了 TTI-621 在经皮可及的复发性或难治性蕈样肉芽肿、Sézary 综合征或实体瘤患者中的安全性和活性。 [4] 我们在此描述了两名日本患者，他们患有经过大量预处理的复发/难治性蕈样肉芽肿，普拉曲沙成功控制了这些患者。 [5] 背景 Mogamulizumab 是一种针对 4 型趋化因子受体的人源化抗体，最近 FDA 批准用于复发/难治性蕈样肉芽肿 (MF) 和 Sézary 综合征 (SS)。 [6] 伏立诺他治疗复发/难治性蕈样肉芽肿 (MF) 和 Sézary 综合征 (SS)。 [7] 背景 Mogamulizumab 是一种抗 CCR4 抗体，用于复发/难治性蕈样肉芽肿 (MF) 或 Sezary 综合征 (SS) 患者。 [8] 在至少一个先前的全身治疗疗程失败后，食品和药物管理局用于复发或难治性蕈样肉芽肿 (MF) 或 SS。 [9]
refractory mycosis fungoide
Purpose Management of patients with refractory mycosis fungoides and Sézary syndrome (SS) is often challenging, as available therapies lack durable response and consistent activity across disease compartments. [1] PD-L1 structural variants in relapsed/refractory mycosis fungoides should prompt consideration of treatment with PD-1 inhibitors. [2] Mogamulizumab was compared with vorinostat in the phase 3 MAVORIC trial (NCT01728805) in 372 patients with relapsed/refractory mycosis fungoides (MF) or Sézary syndrome (SS) who had failed ≥1 prior systemic therapy. [3] This phase 1 study evaluated the safety and activity of TTI-621 in patients with percutaneously accessible relapsed or refractory mycosis fungoides, Sézary syndrome, or solid tumours. [4] We herein describe two Japanese patients with heavily‐pretreated relapsed/refractory mycosis fungoides that were successfully controlled by pralatrexate. [5] BACKGROUND Mogamulizumab is a humanized antibody against chemokine receptor type 4 recently FDA approved for relapsed/refractory mycosis fungoides (MF) and Sézary syndrome (SS). [6] vorinostat in relapsed/refractory mycosis fungoides (MF) and Sézary syndrome (SS). [7] Context Mogamulizumab is an anti-CCR4 antibody for patients with relapsed/refractory mycosis fungoides (MF) or Sezary syndrome (SS). [8] Food and Drug Administration for relapsed or refractory mycosis fungoides (MF) or SS following failure of at least one previous course of systemic therapy. [9]难治性蕈样肉芽肿和 Sézary 综合征 (SS) 患者的管理通常具有挑战性，因为现有疗法缺乏持久的反应和跨疾病隔室的一致活动。 [1] 复发/难治性蕈样肉芽肿中的 PD-L1 结构变异应促使考虑使用 PD-1 抑制剂进行治疗。 [2] 在 372 例复发/难治性蕈样肉芽肿 (MF) 或 Sézary 综合征 (SS) 患者中进行了 3 期 MAVORIC 试验 (NCT01728805)，将莫加木单抗与伏立诺他进行了比较，这些患者之前的全身治疗失败了 ≥1 次。 [3] 这项 1 期研究评估了 TTI-621 在经皮可及的复发性或难治性蕈样肉芽肿、Sézary 综合征或实体瘤患者中的安全性和活性。 [4] 我们在此描述了两名日本患者，他们患有经过大量预处理的复发/难治性蕈样肉芽肿，普拉曲沙成功控制了这些患者。 [5] 背景 Mogamulizumab 是一种针对 4 型趋化因子受体的人源化抗体，最近 FDA 批准用于复发/难治性蕈样肉芽肿 (MF) 和 Sézary 综合征 (SS)。 [6] 伏立诺他治疗复发/难治性蕈样肉芽肿 (MF) 和 Sézary 综合征 (SS)。 [7] 背景 Mogamulizumab 是一种抗 CCR4 抗体，用于复发/难治性蕈样肉芽肿 (MF) 或 Sezary 综合征 (SS) 患者。 [8] 在至少一个先前的全身治疗疗程失败后，食品和药物管理局用于复发或难治性蕈样肉芽肿 (MF) 或 SS。 [9]